A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Brief description of study

In this research study, we are studying the Study Drugs AGEN2034 and AGEN1884 as immune therapies that target your immune cells to block proteins called PD-1 and CTLA4 respectively. This therapy is designed to improve the ability of your immune system to fight your cancer. This is not the first time that the Study Drugs will be given to humans, and similar drugs are used to treat cancer. We are evaluating the safety and effectiveness of study drugs that can be administered safely to participants who have been diagnosed with relapsed or refractory cervical cancer You are being asked to participate in this study because you have cervical cancer. You have already been treated with other therapies that are commonly used for your cancer, and your cancer has recurred or is not responding to those treatments.


Clinical Study Identifier: s18-01528
ClinicalTrials.gov Identifier: NCT03894215
Principal Investigator: Leslie R Boyd.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.